阿拉丁PI3K/Akt抑制劑的優勢
PI3K-Akt-mTOR 通路由磷脂酰肌醇3- 激酶(PI3Ks)、絲氨酸/蘇氨酸蛋白激酶(Akt,也稱為PKB)和哺乳動物雷帕霉素靶蛋白(mTOR)組成。該信號轉導途徑在細胞的生長、存活、增殖、凋亡、血管生成、自吞噬等過程中發揮著極其重要的生物學功能。PI3Ks 蛋白家族參與眾多的與細胞生長及腫瘤生成相關的過程,如:細胞增殖、血管生成、細胞運動、腫瘤侵襲和轉移等,并參與細胞功能的調節。PI3K-Akt-mTOR 通路及其抑制劑的作用原理如下圖所示。
產品列表
編號 |
名稱 |
規格 |
分子式 |
包裝 |
cas號 |
A129503 |
AS-252424 |
≥98% |
C14H8FNO4S |
100MG;25MG;2MG;5MG |
900515-16-4 |
A129517 |
AS-604850 |
≥98% |
C11H5F2NO4S |
100MG;25MG;5MG |
648449-76-7 |
A129523 |
AZD6482 |
≥98% |
C22H24N4O4 |
10MG;50MG;5MG |
1173900-33-8 |
B126138 |
BX-912 |
≥97% |
C20H23BrN8O |
100MG;25MG;5MG |
702674-56-4 |
B126286 |
BEZ235 |
≥99% |
C30H23N5O |
100MG;25MG |
915019-65-7 |
B126947 |
BX-795 |
≥97% |
C23H26IN7O2S |
100MG;10MG;50MG |
702675-74-9 |
C125082 |
CHIR-99021 |
≥98% |
C22H18Cl2N8 |
25MG;5MG |
252917-06-9 |
C127044 |
CAL-101 |
≥99% |
C22H18FN7O |
10MG;50MG |
870281-82-6 |
C128050 |
CZC24832 |
≥98% |
C15H17FN6O2S |
10MG;50MG |
1159824-67-5 |
C129710 |
CHIR-99021 (CT99021) HCl |
≥98% |
C22H18Cl2N8.HCl |
100MG;25MG;5MG |
252917-06-9 |
D129758 |
Dorsomorphin 2HCl |
≥98% |
C24H25N5O·2HCl |
10MG;50MG;5MG |
1219168-18-9 |
E125341 |
Everolimus (RAD001) |
≥98% |
C53H83NO14 |
100MG;10MG;25MG |
159351-69-6 |
G125299 |
GSK2636771 |
≥98% |
C22H22F3N3O3 |
10MG;50MG;5MG |
1372540-25-4 |
H129712 |
H 89 2HCl |
≥99% |
C20H20BrN3O2S.2HCl |
10MG;50MG |
130964-39-5 |
L124970 |
LY294002 |
≥98% |
C19H17NO3 |
10MG;50MG |
154447-36-6 |
M129496 |
3-甲基腺嘌呤 |
98% |
C6H7N5 |
1G;250MG;50MG |
5142-23-4 |
M129684 |
MK-2206 2HCl |
≥98% |
C25H21N5O·2HCl |
10MG;50MG |
1032350-13-2 |
N127553 |
BKM120 |
≥99% |
C18H21F3N6O2 |
10MG;50MG;5MG |
944396-07-0 |
O126958 |
OSU-03012 (AR-12) |
≥98% |
C26H19F3N4O |
100MG;25MG;5MG |
742112-33-0 |
P124979 |
Perifosine (KRX-0401) |
≥99% |
C25H52NO4P |
10MG;50MG;5MG |
157716-52-4 |
P125961 |
PI-103 |
≥98% |
C19H16N4O3 |
100MG;10MG;50MG |
371935-74-9 |
P127286 |
PHT-427 |
≥98% |
C20H31N3O2S2 |
10MG;50MG |
1191951-57-1 |
P129635 |
PP242 |
≥98% |
C16H16N6O |
10MG;50MG;5MG |
1092351-67-1 |
溫馨提示點擊相應產品的cas號即可查詢購買。
中華試劑網(xcrail.com)